2023
43778 Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober B, Puig L, Blauvelt A, Thaçi D, Elewski B, Wang M, Vanvoorden V, Deherder D, Staelens F, Wiegratz S, Paul C. 43778 Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial. Journal Of The American Academy Of Dermatology 2023, 89: ab21. DOI: 10.1016/j.jaad.2023.07.092.Peer-Reviewed Original ResearchOpen-label extension periodPhase 3b trialSevere plaque psoriasisPlaque psoriasisExtension periodPsoriasisPatientsTrials
2022
33817 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Lebwohl M, Ghoreschi K, Strober B, Eyerich K, Cather J, Wang M, Cioffi C, Deherder D, Staelens F, Gomez N, Puig L. 33817 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial. Journal Of The American Academy Of Dermatology 2022, 87: ab145. DOI: 10.1016/j.jaad.2022.06.613.Peer-Reviewed Original ResearchOpen-label extension periodPhase 3b trialSevere plaque psoriasisPlaque psoriasisExtension periodSecukinumabPsoriasisPatients34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Strober B, Paul C, Blauvelt A, Thaçi D, Elewski B, White K, Vanvoorden V, Deherder D, Staelens F, Eyerich K. 34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial. Journal Of The American Academy Of Dermatology 2022, 87: ab146. DOI: 10.1016/j.jaad.2022.06.614.Peer-Reviewed Original ResearchOpen-label extension periodPhase 3b trialSevere plaque psoriasisPlaque psoriasisExtension periodPsoriasisPatientsTrialsWeeks